1、Annual Report 2020ContentsStrategic reportOur business model 01Chairmans statement 03CEOs statement 04Financial performance 06Our long-term priorities 09Our culture 10Key performance indicators 11Industry trends 12Stakeholder engagement 16Innovation 18Performance 28Trust 33Risk management 43Group fi
2、nancial review 50Corporate GovernanceChairmans Governance statement 78The Board 80Corporate Executive Team 83Board architecture 85Board roles and responsibilities 86Board activity and principal decisions 87Our purpose,values and culture 90The Boards approach to engagement 91Board performance 94Board
3、 Committee information 96Our Board Committee reports 97Section 172 statement 108Directors report 109Remuneration reportChairmans annual statement 112Annual report on remuneration 1142020 Remuneration policy summary 133Financial statementsDirectors statement of responsibilities 140Independent Auditor
4、s report 142Financial statements 154Notes to the financial statements 158Financial statements of GlaxoSmithKline plc prepared under UK GAAP 238Investor informationQuarterly trend 244Five-year record 249Product development pipeline 255Products,competition and intellectual property 258Principal risks
5、and uncertainties 261Share capital and share price 276Dividends 278Financial calendar 2021 279Annual General Meeting 2021 279Tax information for shareholders 280Shareholder services and contacts 282US law and regulation 284Group companies 287Glossary of terms 299We are a science-led global healthcar
6、e companyCautionary statementSee the inside back cover of this document for the cautionary statement regarding forward-looking statements.Non-IFRS measuresWe use a number of adjusted,non-IFRS,measures to report the performance of our business.Total reported results represent the Groups overall perfo